Trial · NCT07894874
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The occurrence and frequency of Treatment-emergent adverse events (TEAEs) | From first dose through 30 days after the last dose of study treatment(up to approximately 36 months) | phase 1a |
| Primary | The occurrence and frequency of Dose-limiting toxicities (DLTs) DLTs during the study | first cycle (each cycle is 21 days) | phase 1a |
| Primary | Objective remission rate (ORR) assessed by the investigator according to RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1b |
| Secondary | Objective Response Rate (ORR) per RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1a |
| Secondary | Disease Control Rate (DCR) per RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1a and Phase 1b |
| Secondary | Progression-Free Survival (PFS) per RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1a and Phase 1b |
| Secondary | Duration of Response (DOR) per RECIST v1.1 | Every 6 weeks (±7 days) during the first 48 weeks from Cycle 1 Day 1 (C1D1,each cycle is 21 days), and every 9 weeks (±7 days) thereafter (up to approximately 36 months) | Phase 1a and Phase 1b |
| Secondary | Overall Survival (OS) | approximately 36 months | Duration from the date of initial treatment to the date of death due to any cause |
| Secondary | Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measurable Time Point (AUC₀-t) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Area under the plasma concentration-time curve of YF550 from time zero to the last measurable time point. |
| Secondary | Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC₀-∞) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Area under the plasma concentration-time curve of YF550 from time zero extrapolated to infinity. |
| Secondary | Mean Residence Time (MRT) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Mean residence time of YF550 in plasma. |
| Secondary | Maximum Observed Plasma Concentration (Cmax) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Maximum observed plasma concentration of YF550. |
| Secondary | Time to Maximum Observed Plasma Concentration (Tmax) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Time to reach the maximum observed plasma concentration of YF550. |
| Secondary | Terminal Elimination Half-Life (t½) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Terminal elimination half-life of YF550 in plasma. |
| Secondary | Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Apparent volume of distribution of YF550 during the terminal phase following extravascular administration. |
| Secondary | Apparent Total Clearance Following Extravascular Administration (CL/F) | every 2 weeks in Cycle 1 (each cycle is 21 days) and every 4 cycles until end of treatment (up to approximately 36 months) | Apparent total clearance of YF550 following extravascular administration. |
| Secondary | Change from Baseline in QT/QTc Interval | Up to 16 days after dosing | Phase 1a |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07894874/registered